Clinical Trials Browser

Phase 1/2 × OTHER × orelabrutinib × Clear all

NCT05021770 2021-08-26

Orelabrutinib in Combination With Thiotepa in Refractory and Relapsed Primary CNS Lymphoma

Phase 1/2 Unknown

Lymphoma, Non-Hodgkin